Breast cancer but not the menopausal status is associated with small changes of the gut microbiota

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Jan. 24, 2024

Possible relationships between gut dysbiosis and breast cancer (BC) development progression have been previously reported. However, the results of these metagenomics studies are inconsistent. Our study involved 88 patients diagnosed with 86 cancer-free control women. Participants were divided into groups based on their menopausal status. Fecal samples collected from 47 41 pre- postmenopausal newly 51 35 controls, respectively. In this study, we performed shotgun metagenomic analyses to compare microbial community BC corresponding controls. Firstly, identified 12, 64, 158, 455 bacterial taxa taxonomy level phyla, families, genera, species, Insignificant differences Shannon index β-diversity found at genus species levels controls; concerned only Chao level. No in α-diversity indexes patients, although differed subgroups levels. Consistently, abundance single controls cases, while abundances 14 23 or tended differ premenopausal cases There similar distribution enterotypes. Of 460 MetaCyc pathways discovered, no differentiated two one subgroups, While our findings did not reveal an association changes overall microbiota composition selected status they confirmed less extensive than those described previously.

Language: Английский

---

Unveiling the Interplay Between the Human Microbiome and Gastric Cancer: A Review of the Complex Relationships and Therapeutic Avenues

Cancers, Journal Year: 2025, Volume and Issue: 17(2), P. 226 - 226

Published: Jan. 12, 2025

The human microbiota plays a crucial role in maintaining overall health and well-being. gut has been implicated developing progressing various diseases, including cancer. This review highlights the related mechanisms compositions that influence cancer pathogenesis with highlight on gastric We provide comprehensive overview of by which microbiome influences development, progression, response to treatment, focus identifying potential biomarkers for early detection, prevention strategies, novel therapeutic interventions leverage modulation. can guide future research clinical practices understanding harnessing optimize therapies.

Language: Английский

---

Gut microbiota interact with breast cancer therapeutics to modulate efficacy

EMBO Molecular Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 16, 2025

Abstract The gut microbiome, or the community of microorganisms residing in gastrointestinal tract, has emerged as an important factor breast cancer etiology and treatment. Specifically, impact bacterial populations on therapeutic outcomes is emerging area research. microbiota’s role modifying pharmacokinetics chemotherapy endocrine-targeting therapies can alter drug efficacy toxicity profiles. In addition, microbiome’s capacity to regulate systemic inflammation immune responses may influence effectiveness both conventional immunotherapeutic strategies for treatment cancer. Overall, while bidirectional interactions between microbiome are still being studied, its increasingly recognized. Future research provide more definitive insights help develop personalized harness improve outcomes.

Language: Английский

---

Exploring the Impact of Chemotherapy on the Emergence of Antibiotic Resistance in the Gut Microbiota of Colorectal Cancer Patients

Antibiotics, Journal Year: 2025, Volume and Issue: 14(3), P. 264 - 264

Published: March 5, 2025

With nearly half of colorectal cancer (CRC) patients diagnosed at advanced stages where surgery alone is insufficient, chemotherapy remains a cornerstone for this treatment. To prevent infections and improve outcomes, antibiotics are often co-administered. However, chemotherapeutic interactions with the gut microbiota cause significant non-selective toxicity, affecting not only tumor normal epithelial cells but also microbiota. This toxicity triggers bacterial SOS response loss microbial diversity, leading to mutations dysbiosis. Consequently, pathogenic overgrowth systemic increase, necessitating broad-spectrum intervention. review underscores how prolonged antibiotic use during chemotherapy, combined chemotherapy-induced mutations, creates selective pressures that drive de novo antimicrobial resistance (AMR), allowing resistant bacteria dominate gut. compromises treatment efficacy elevates mortality risk. Restoring diversity may mitigate therapeutic emerging strategies, such as fecal transplantation (FMT), probiotics, prebiotics, show considerable promise. Given global threat posed by treatment, prioritizing stewardship essential optimizing preventing in CRC undergoing chemotherapy. Future research should aim minimize chemotherapy’s impact on develop targeted interventions restore affected

Language: Английский

---

Predictors of Immunotherapy Response in Triple Negative Breast Cancer

Current Breast Cancer Reports, Journal Year: 2025, Volume and Issue: 17(1)

Published: March 7, 2025

Language: Английский

---

Operationalizing Team Science at the Academic Cancer Center Network to Unveil the Structure and Function of the Gut Microbiome

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(6), P. 2040 - 2040

Published: March 17, 2025

Oncologists increasingly recognize the microbiome as an important facilitator of health well a contributor to disease, including, specifically, cancer. Our knowledge etiologies, mechanisms, and modulation states that ameliorate or promote cancer continues evolve. The progressive refinement adoption “omic” technologies (genomics, transcriptomics, proteomics, metabolomics) utilization advanced computational methods accelerate this evolution. academic center network, with its immediate access extensive, multidisciplinary expertise scientific resources, has potential catalyze research. Here, we review our current understanding role gut in prevention, predisposition, response therapy. We underscore promise operationalizing network uncover structure function microbiome; highlight unique microbiome-related expert resources available at City Hope Comprehensive Cancer Center example team science achieve novel clinical discovery.

Language: Английский

---

The role of Akkermansia muciniphila in cancer: Mechanisms, therapeutic potential, and challenges

iMetaOmics., Journal Year: 2025, Volume and Issue: unknown

Published: March 27, 2025

Language: Английский

---

Negative Effect of Intravenous Antibiotics on Survival in Patients with Triple-Negative Breast Cancer

Cancers, Journal Year: 2025, Volume and Issue: 17(9), P. 1498 - 1498

Published: April 29, 2025

The anti-tumor response of the immune system is pivotal for treating triple-negative breast cancer (TNBC), particularly as targeted therapies are limited. However, impact immune-modulating factors such application granulocyte-stimulating (G-CSFs) or infections, including febrile neutropenia, prophylactic therapeutical oral antibiotics (OABs), and need intravenous (IABs), on survival outcomes remains unclear. 1583 patients with early-stage TNBC enrolled in SUCCESS A C study underwent primary surgery, adjuvant chemotherapy, radiotherapy if indicated. All had Eastern Cooperative Oncology Group (ECOG) status ≤ 2. effects G-CSF, OAB, IAB overall (OS), invasive disease-free (iDFS), cancer-specific (BCSS), distant (DDFS) were assessed. Only treatment was significantly associated decreased univariable analyses (OS: p = 0.003; iDFS: 0.036; BCSS: 0.011; DDFS: 0.044), while G-CSF OAB administration not. Adjusted multivariable Cox regressions neutropenia dose reduction/shift, ECOG, age patients, other clinicopathological parameters confirmed a significant negative effect IABs OS (p 0.020), BCSS 0.018), DDFS 0.044). In summary, during chemotherapy seems to be risk factor inferior OS, BCSS, possibly by affecting microbiome-related modulation. Hence, preventive measures avoid should considered these patients.

Language: Английский

---

Akkermansia muciniphila ameliorates doxorubicin-induced cardiotoxicity by regulating PPARα-dependent mitochondrial biogenesis

npj Biofilms and Microbiomes, Journal Year: 2025, Volume and Issue: 11(1)

Published: May 23, 2025

Doxorubicin (DOX) is a key chemotherapeutic agent but also leading cause of DOX-induced cardiotoxicity (DIC), limiting its clinical use. Akkermansia muciniphila (A. muciniphila), known for benefits as probiotic in treating metabolic syndrome, has uncertain effects the context DIC. Here, 16S rRNA sequencing fecal samples from anthracycline-treated patients and DIC mice revealed marked depletion A. muciniphila. Cardiac transcriptomics, supported by vitro experiments, showed that colonization improved mitochondrial function alleviated activating PPARα/PGC1α signaling pathway both normal antibiotic-treated C57BL/6 mice. Further analysis uncovered restructured microbiome-metabolome network following administration, which contributed to protection. Notably, supplementation increased serum levels tryptophan metabolite indole-3-propionic acid (IPA), binds cardiac aryl hydrocarbon receptor (AhR), activation pathway. In conclusion, our study sheds light on potential mitigating

Language: Английский

---

Microbiome: Mammalian milk microbiomes: sources of diversity, potential functions, and future research directions

Reproduction and Fertility, Journal Year: 2024, Volume and Issue: 5(2)

Published: March 18, 2024

Graphical abstract Abstract Milk is an ancient, fundamental mammalian adaptation that provides nutrition and biochemical communication to offspring. Microbiomes have been detected in milk of all species studied date. In this review, we discuss: (a) routes by which microbes may enter milk; (b) evidence for proposed microbiome adaptive functions; (c) variation microbiomes across mammals; (d) future research directions, including suggestions how address outstanding questions on the viability functionality microbiomes. be sourced from maternal gastrointestinal tract, oral, skin, mammary gland neonatal oral skin Given variety microbial sources, stochastic processes strongly influence assembly, but appear influenced evolutionary history, diet, environment, nutrients. colonize intestinal tract produce gene metabolic products physiology, metabolism, immune system development. Limited epidemiological data indicate early-life exposure can result positive, long-term health outcomes. modified dietary changes providing mother with probiotics prebiotics. replacers (i.e. infant formula) benefit supplementation prebiotics, are lacking probiotics’ usefulness, should based. Overall, literature outside human model systems scarce. We highlight need mechanistic studies paired comparative mammals further our understanding evolution. A broader study has potential inform animal care relevance ex situ endangered species. Lay summary ancient supports growth development neonates infants. Beyond its nutritional function, influences aspects development, especially function. All kinds milks so far contained a microbiome. focus what known about collection bacterial members found include they nutrients, as well random chance. Once neonate begins nursing, their gut byproducts Empirical humans sparse. Greater will expand evolution improve animals under care.

Language: Английский

---